Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Dec;10(17):1259-1264.
doi: 10.2217/cer-2021-0179. Epub 2021 Aug 31.

Comparative effectiveness research in COVID-19 using real-world data: methodological considerations

Stephanie H Read  1 , Artak Khachatryan  1 , Aastha Chandak  2 , Roman Casciano  2 , Paul Hodgkins  3 , Richard Haubrich  3 , Essy Mozaffari  3
Affiliations
Editorial

Comparative effectiveness research in COVID-19 using real-world data: methodological considerations

Stephanie H Read et al. J Comp Eff Res. 2021 Dec.
No abstract available

Keywords: COVID-19; bias; comparative effectiveness studies; confounding; real-world data.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

S Read, A Khachatryan, A Chandak and R Casciano are employees of Certara, which was contracted by Gilead Sciences for writing this manuscript (provided funding for this research). P Hodgkins, R Haubrich and E Mozaffari are employees and shareholders at Gilead Sciences. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Gilead Sciences funded Certara to write this manuscript.

References

    1. Gorbalenya A, Baker S, Baric Ret al.The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5(4), 536–544 (2020). - PMC - PubMed
    1. World Health Organization. WHO COVID-19 dashboard (2020). https://covid19.who.int/
    1. Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report—Part II. Value Health 12(8), 1053–1061 (2009). - PubMed
    1. Renoux C, Azoulay L, Suissa S. Biases in evaluating the safety and effectiveness of drugs for covid-19: designing real-world evidence studies. Am. J. Epidemiol. 190(8), 1452–1456 (2021). - PMC - PubMed

    2. • This helpful publication provides a thorough description of additional biases, including selection bias in COVID-19 studies.

    1. Gautret P, Lagier J-C, Parola Pet al.Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents 56(1), 105949 (2020). - PMC - PubMed

Publication types

Grants and funding